High-Shear Microfluidic Thrombosis Assay

It is estimated that approximately 25% of people are resistant to aspirin, or do not respond to its effect. These individuals have a four fold higher risk of a heart attack or stroke compared to those who respond to aspirin. Current tests for determining those who are aspirin resistant are not reliable. This study is assessing the effectiveness of a new assay in determining the rate and time it takes for people who are or are not on aspirin in forming a blood clot.

Inclusion criteria

for "no aspirin" group:

• have not taken aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), or clopidogrel in the previous 10 days
• no history of myocardial infarction, ischemic stroke, or other ischemic event

Inclusion criteria

for "aspirin daily" group:

• have taken aspirin daily over the last 10 days or more
• no history of myocardial infarction, ischemic stroke, or other ischemic event

Inclusion criteria

for "new to aspirin" group:

• have not previously been prescribed aspirin, but have been prescribed aspirin at their present appointment, e.g. a high calcium plaque score on CT
• no history of myocardial infarction, ischemic stroke, or other ischemic event

Exclusion criteria

• a known bleeding or thrombotic disorder

Exclusion criteria

for "new to aspirin" group:

• a known bleeding or thrombotic disorder
• have taken aspirin, other NSAIDs, clopidogrel, or an anticoagulant in the previous 10 days